OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Nguyen on the Role of Concurrent Chemotherapy With TMT in MIBC

February 21st 2024

Anthony T. Nguyen, MD, PhD, discusses the role of concurrent chemotherapy with trimodal therapy in patients with muscle-invasive bladder cancer.

Dr Rini on the Background of the FDA Approval of Belzutifan in RCC

February 21st 2024

Brian I. Rini, MD, FASCO, discusses the research that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

Dr Cohen on Treatment Considerations for Relapsed/Refractory MCL

February 21st 2024

Jonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.

Dr Cappuzzo on Findings from the RATIONALE-315 Trial in Resectable NSCLC

February 21st 2024

Federico Cappuzzo, MD, discusses findings from the phase 3 RATIONALE-315 trial in patients with resectable non–small cell lung cancer.

Dr Meisel on Patient-Reported Perceptions of Provider Communication in Breast Cancer Care

February 20th 2024

Jane L. Meisel, MD, discusses patient-reported perceptions of patient-provider communication in cancer care.

Dr Zonder on the Outcomes of the PERSEUS Trial in Multiple Myeloma

February 20th 2024

Jeffrey Zonder, MD, discusses the outcomes of the phase 3 PERSEUS trial in patients with relapsed/refractory multiple myeloma.

Dr Gong on the EMBARK Trial Investigating Enzalutamide in nmCSPC

February 20th 2024

Jun Gong, MD, discusses the significance of the phase 3 EMBARK study of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Dr Bryant on the Influence of Germline DNA Repair Mutations on Therapeutic Development in PDAC

February 20th 2024

John M. Bryant, MD, discusses how identifying germline DNA repair mutations may impact the development of targeted therapy development in PDAC.

Dr Park on the Use of Sacituzumab Govitecan Plus Pembrolizumab in Urothelial Carcinoma

February 20th 2024

Chandler H. Park, MD, FACP, discusses the use of sacituzumab govitecan plus pembrolizumab in patients with metastatic urothelial carcinoma.

Dr Beckermann on the Investigation of PY314 Plus Pembrolizumab in ccRCC

February 20th 2024

Kathryn Beckermann, MD, PhD, discusses the treatment of PY314 in combination with pembrolizumab in patients with clear cell renal cell carcinoma.

Dr Dondossola on the Importance of Studying Bone Metastasis in RCC

February 19th 2024

Eleonora Dondossola, PhD, discusses the importance of studying bone metastasis in RCC and other genitourinary cancers.

Dr Pearse on the BOVen Trial of BTK Inhibitor Combinations in TP53-Mutant MCL

February 19th 2024

William B. Pearse, MD, discusses the significance of the ongoing phase 2 BOVen trial in TP53-mutant mantle cell lymphoma.

Dr Jänne on the FDA Approval of Osimertinib Plus Chemotherapy in EGFR+ mNSCLC

February 16th 2024

Pasi A. Jänne, MD, PhD, discusses the FDA approval of osimertinib plus chemotherapy in patients with EGFR-mutant locally advanced or metastatic NSCLC.

Dr Baz on the Incidence of AEs With Ide-Cel in Triple-Class–Exposed Multiple Myeloma

February 16th 2024

Rachid Baz, MD, discusses findings from an analysis of cytopenias and infections in patients with multiple myeloma enrolled in the KarMMa-3 trial.

Dr Kluger on the FDA Approval of Lifileucel in Advanced Melanoma

February 16th 2024

Harriet Kluger, MD, discusses the FDA approval of the tumor infiltrating lymphocyte therapy lifileucel for patients with advanced melanoma.

Dr DeBernardo on the Use of Later-Line Maintenance Therapy in Ovarian Cancer

February 16th 2024

Robert DeBernardo, MD, discusses the use of maintenance therapy in the second- and later-line settings for patients with ovarian cancer.

Dr Shreve on the Potential Impact and Utility of AI in Cancer Care

February 16th 2024

Jacob Shreve, MD, discusses the potential impact of implementing artificial intelligence into cancer care.

Dr Tripathi on the NEMIO Trial of Durvalumab Plus Chemo With/Without Tremelimumab in MIBC

February 16th 2024

Abhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer.

Dr Advani on the Evaluation of Ribociclib/Endocrine Therapy in HR+/HER2– Breast Cancer

February 16th 2024

Pooja Advani, MBBS, MD, discusses the use of ribociclib plus endocrine therapy for patients with hormone receptor–positive, HER2– breast cancer.

Dr Shore on the Implications of the FDA Approval of Enzalutamide for nmCSPC

February 16th 2024

Neal Shore, MD, FACS, discusses the implications of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.